Ocular Therapeutix, Inc. - Common Stock (NQ:OCUL)

6.960 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ocular Therapeutix, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

3 Reasons to Avoid OCUL and 1 Stock to Buy Instead

October 01, 2026

Over the last six months, Ocular Therapeutix’s shares have sunk to $7.74, producing a disappointing 7.1% loss - a stark contrast to the S&P 500’s 16.6% gain....

Via StockStory

Topics Stocks

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

September 28, 2026

Via Chartmill

Ocular Therapeutix and ANI Pharmaceuticals Stocks Trade Down, What You Need To Know

September 23, 2026

What Happened? A number of stocks fell in the afternoon session after sentiment in the healthcare sector weakened, as the Centers for Medicare and Medicaid S...

Via StockStory

Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Success ↗

September 22, 2026

Ocular Therapeutix (NASDAQ:OCUL) said it remains on track to submit a U.S. marketing application for AXPAXLI in the fourth quarter of this year, following what Chief Executive Officer Pravin Dugel...

Via MarketBeat

Ocular Therapeutix Inc (NASDAQ:OCUL) Misses on Revenue and EPS in Q1 2026, Stock Dips ↗

May 05, 2026

Via Chartmill

1 Cash-Heavy Stock on Our Buy List and 2 Facing Challenges

September 01, 2026

A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face c...

Via StockStory

Pharmaceuticals Stocks Q2 Highlights: Ocular Therapeutix (NASDAQ:OCUL)

August 20, 2026

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the pharmaceuticals industry, including Oc...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Ocular Therapeutix (NASDAQ:OCUL) Beats Expectations in Strong Q2 CY2026

August 03, 2026

Ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ:OCUL) reported Q2 CY2026 results beating Wall Street’s revenue expectations, but sales wer...

Via StockStory

3 Healthcare Stocks with Questionable Fundamentals

August 03, 2026

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not on...

Via StockStory

3 Russell 2000 Stocks That Concern Us

July 31, 2026

The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However,...

Via StockStory

Pharmaceuticals Stocks Q1 In Review: Ocular Therapeutix (NASDAQ:OCUL) Vs Peers

July 26, 2026

Let’s dig into the relative performance of Ocular Therapeutix (NASDAQ:OCUL) and its peers as we unravel the now-completed Q1 pharmaceuticals earnings season....

Via StockStory

Topics Artificial Intelligence Intellectual Property

Ocular Therapeutix Eyes Q4 AXPAXLI NDA After FDA Alignment ↗

July 22, 2026

Ocular Therapeutix (NASDAQ:OCUL) said it remains on track to submit a New Drug Application for AXPAXLI in wet age-related macular degeneration in the fourth quarter, after what Executive Chairman,...

Via MarketBeat

3 Cash-Burning Stocks with Open Questions

July 21, 2026

While some companies burn cash to fuel expansion, others struggle to turn spending into sustainable growth. A high cash burn rate without a strong balance sh...

Via StockStory

Topics Artificial Intelligence

3 Small-Cap Stocks with Open Questions

July 08, 2026

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and...

Via StockStory

Ocular Therapeutix (OCUL): Buy, Sell, or Hold Post Q1 Earnings?

June 24, 2026

Over the past six months, Ocular Therapeutix’s shares (currently trading at $10.37) have posted a disappointing 18.5% loss, well below the S&P 500’s 7.8% gai...

Via StockStory

Topics Stocks

Stocks making big moves yesterday: Nubank, Ocular Therapeutix, Mondelez, ResMed, and Sonos

June 18, 2026

Check out the companies making headlines yesterday: Nubank (NYSE:NU): Digital banking platform Nubank (NYSE:NU) rose by 3.2% on Wednesday after the company r...

Via StockStory

Topics Economy

Why Ocular Therapeutix (OCUL) Stock Is Up Today

June 17, 2026

What Happened? Shares of ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ:OCUL) jumped 7.2% in the afternoon session after the company anno...

Via StockStory

Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026? ↗

June 15, 2026

Two biotech innovators, two very different risk profiles: one with commercial products and another betting on next-gen gene editing breakthroughs.

Via The Motley Fool

3 of Wall Street’s Favorite Stocks That Concern Us

June 10, 2026

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember...

Via StockStory

1 Russell 2000 Stock to Research Further and 2 Facing Headwinds

May 28, 2026

The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However,...

Via StockStory

Acuta Capital Sells 56% of Ocular Therapeutix Shares in Q1 ↗

May 26, 2026

Ocular Therapeutix delivers FDA-approved eye therapies and devices, supported by a pipeline targeting multiple ocular diseases.

Via The Motley Fool

Topics Regulatory Compliance Stocks

What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors ↗

May 19, 2026

Ocular Therapeutix delivers ophthalmic therapies with hydrogel technology and a pipeline targeting retinal and glaucoma conditions.

Via The Motley Fool

Topics Regulatory Compliance

Why Ocular Therapeutix (OCUL) Stock Is Nosediving

May 05, 2026

What Happened? Shares of ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ:OCUL) fell 5.8% in the afternoon session after the company report...

Via StockStory

Ocular Therapeutix (NASDAQ:OCUL) Reports Sales Below Analyst Estimates In Q1 CY2026 Earnings

May 05, 2026

Ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ:OCUL) missed Wall Street’s revenue expectations in Q1 CY2026, with sales flat year on year...

Via StockStory

Ocular Therapeutix (OCUL) To Report Earnings Tomorrow: Here Is What To Expect

May 03, 2026

Ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ:OCUL) will be announcing earnings results this Tuesday before the bell. Here’s what to loo...

Via StockStory

1 Healthcare Stock with Exciting Potential and 2 Facing Headwinds

April 02, 2026

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have ou...

Via StockStory

Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools ↗

March 18, 2026

Spyre Therapeutics focuses on antibody therapies for inflammatory bowel disease, advancing a pipeline aimed at gastrointestinal health.

Via The Motley Fool

What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down ↗

March 18, 2026

This ophthalmic biopharma firm develops sustained drug delivery therapies for eye diseases, targeting both U.S. and global markets.

Via The Motley Fool

Topics Regulatory Compliance

1 Cash-Heavy Stock to Research Further and 2 We Brush Off

March 18, 2026

Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they strugg...

Via StockStory

3 Reasons to Avoid OCUL and 1 Stock to Buy Instead

March 17, 2026

Shareholders of Ocular Therapeutix would probably like to forget the past six months even happened. The stock dropped 29.1% and now trades at $8.62. This was...

Via StockStory

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.